Abstract: AIM: To study the efficacy and safety of paliperidone extended-release tablet(Paliperidone-ER) and Risperidone on negative symptoms of schizophrenia.METHODS: Sixty cases of schizophrenics with prominent negative symptoms were randomly divided into study group(n=30)and control group(n=30).Thirty cases of Paliperidone-ER treated patients were compared with thirty cases of Risperidone treated patients.The duration of study was 8 weeks.The therapeutic efficacy and safety were assessed with the PANSS and TESS, respectively.RESULTS: The significantly effective rate and effective rate of Paliperidone-ER were 63.3% and 80%, and of Risperidone were 60% and 76.7% respectively, and there were no significant differences between two groups(P>0.05).Paliperidone-ER group showed lower negative symptom score at the fourth week(15.40±1.04) and at the eighth week(12.80±0.76) than Risperidone group, although the scores decreased at the fourth week (20.60±1.13) and at the eighth week (18.10±0.71). There were significant differences between two groups(P<0.05).At the eighth week ,the full score of PANSS of study group was (42.90±0.84), the full score of PANSS of control group was(44.80±0.61). There were significant differences between two groups(P<0.05).The TESS of study group were EPS and drowsiness. The TESS of control group were EPS,wakefulness,increase of weight and faintness eyesight. There were no severe adverse effects in two groups.CONCLUSION: Paliperidone-ER is an effective and safe antipsychotic drug with more showing significant improvement compared with Risperidone in negative symptoms.

Key words: Schizophrenia, Paliperidone extended-release tablet, Risperidone, Negative symptom